[Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]. (Q53063698)

11 May 2018

title

[Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]. (English)

1 reference

11 May 2018

author name string

R Gutzmer

1

1 reference

11 May 2018

J C Hassel

2

1 reference

11 May 2018

K C Kähler

3

1 reference

11 May 2018

C Loquai

4

1 reference

11 May 2018

R Mössner

5

1 reference

11 May 2018

S Ugurel

6

1 reference

11 May 2018

L Zimmer

7

1 reference

11 May 2018

Für Komitee Kutane Nebenwirkungen Ado der das Ado

8

1 reference

11 May 2018

language of work or name

German

0 references

publication date

1 July 2014

1 reference

11 May 2018

published in

Die Dermatologie

1 reference

11 May 2018

volume

65

1 reference

11 May 2018

issue

7

1 reference

11 May 2018

page(s)

582-589

1 reference

11 May 2018

Cutaneous toxicities of RAF inhibitors.

cites work

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Vemurafenib and radiosensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Second primary melanomas on treatment with vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Vemurafenib: an unusual UVA-induced photosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Analysis of dermatologic events in vemurafenib-treated patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Vemurafenib and radiation therapy in melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

RASopathic skin eruptions during vemurafenib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Vemurafenib-induced DRESS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Case of vemurafenib-induced Sweet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-013-2733-8

Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma

21 January 2018

1 reference

12 December 2020

Ultraviolet A and photosensitivity during vemurafenib therapy

1 reference

12 December 2020

The hand-foot-syndrome associated with medical tumor therapy - classification and management

1 reference

12 December 2020

Severe radiotherapy-induced extracutaneous toxicity under vemurafenib

1 reference

12 December 2020

Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician

1 reference

12 December 2020

Vemurafenib-induced neutrophilic panniculitis

1 reference

12 December 2020

Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers

1 reference

12 December 2020

[Cutaneous side effects of medical tumor therapy]

1 reference

12 December 2020

10.1007/S00105-013-2733-8

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018